National and Kapodistrian University of Athens
Απομόνωση και εξωσωματικός (ex vivo) πολλαπλασιασμός στρωματικών στελεχιαίων κυττάρων από τον ανθρώπινο μυελό των οστών
Abstract
dc:descriptionStromal stem cells (SSC) are produced in vitro when bone marrow (BM) is cultured under standard conditions. They are characterized by fibroblast-like morphology, adherent growth, specific phenotype as defined by flow cytometric analyses and capacity to differentiate into adipocytes, osteocytes and chondrocytes. They also possess remarkable expansion potential and suppress the proliferation of lymphocytes in mixed lymphocyte cultures. They probably originate from perivascular cells or pericytes.In recent years, several experimental studies have shown that SSC are endowed with immunomodulatory properties and with the capacity to promote graft survival in animal models. Furthermore, they have the ability to home to damaged tissue and to produce paracrine factors with anti-inflammatory effects, resulting in functional recovery of the wounded area. In view of these properties, SSC have been tested in pilot studies aimed at accelerating recovery and at treating steroid-resistant aGVHD after allogeneic hematopoietic stem cell (HSC) transplantation. Moreover, there are many ongoing clinical studies phase I and II, investigating the effect of cell therapy with SSC on autoimmune and inflammatory bowel diseases, as well as, on regeneration of tissue with limited renewal capacity (heart, nervous, tissues of the musculoskeletal system, etc.).With the aim to produce ex vivo expanded SSC, in a number sufficient to treat GVHD, but also, the detection of the most appropriate population of bone marrow stem cells for the treatment of patients with heart failure, we studied two distinct populations of SSC (CD105+ and CD271+) and two HSC (CD34+ and CD133+), as they considered until recently.We obtained 10ml BM samples from 23 healthy donors. The above populations were isolated using corresponding antibodies and positive immunomagnetic selection method. The isolated cells were placed in ex vivo expansion and differentiation cultures towards osteogenic, chondrogenic and adipogenic lineages. Surface marker expression of cultured SSC were analyzed by flow cytometry, while chondrogenic, adipogenic and osteogenic differentiation were confirmed by COL2A1, LPL and ALP expression, respectively.All selected populations generated fibroblast-like, adherent cells which maintain their expansion potential for about 5 weeks and 9 sequential passages. The expansion rate and the total number of cells at the end of the culture, does not seem to vary considerably, while, the immunophenotype (CD29+, CD90+, CD44+, CD13+, CD105+, Class I – HLA+, CD14-, CD19-, CD31-, HLA-DR-, CD34- and CD45-) and the ability to differentiate into adipocytes, osteocytes and chondrocytes, as demonstrated by gene expression of LPL, ALP and COL2A1 respectively, confirm their identity as SSC.Significant variation of the above results were observed during cultivation of a CD271+ sample, in which spontaneous generation of diverse cell clusters after third passage, inhibited further proliferation of SSC.This finding led us to the choice of CD105+ cells in order to receive sufficient numbers of SSC to treat GVHD. This approach is now well established in our laboratory.As far as CD133+ and CD34+ cells are concerned, our results very clearly showed that in addition to hematopoietic and endothelial progenitor cells, they also contain SSC, confirming the fact at that time had just begun to emerge for the first population, but, upsetting the literature data for the second.The clinical study that followed was based on these findings. CD133+ and CD133-CD34+ cells were immunomagnetically selected from BM of 26 patients with heart failure and subsequently re-infused to the patients with intracoronary administration. In 8 cases, isolated cells were labeled with 99mTc-hexamethylpropylenamineoxime. This fact revealed that significant number of injected cells homed to the infracted area of the heart, resulting in reduction of size of non-viable areas, improvement of myocardial perfusion and cardiac parameters, thus justifying the conductive of a prospective clinical trial phase II.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Theodosaki, Maria
- Θεοδοσάκη, Μαρία
Subjects
dc:subject × 14- Στρωματικά στελεχιαία κύτταρα
- Ανθρώπινος μυελός των οστών
- Εξωσωματικός πολλαπλασισμός
- Stromal stem cells
- Human bone marrow
- Ex vivo expansion
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Επιστήμες Μηχανικού και Τεχνολογία
- Βιοϊατρική Μηχανική
- Medical and Health Sciences
- Basic Medicine
- Engineering and Technology
- Medical Engineering
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41459